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Butyrate, a short-chain fatty acid released by colonic bacteria and administered therapeutically in
inflammatory bowel diseases, exerts immunomodulatory properties. The aim of the study was to deter-
mine the functional consequences of butyrate exposure on the proinflammatory responsiveness of
human intestinal epithelial cells (IEC). IL-8 promoter activity in IEC pretreated with butyrate then
exposed to proinflammatory stimuli was assayed by transfection of luciferase constructs. IL-8 secretion
was determined by ELISA and neutrophil migration by flow cytometry. Receptor mRNA was assessed
by reverse transcriptase–polymerase chain reaction (RT-PCR). Butyrate modulated proinflammatory
IL-8 secretion differentially in Caco-2 and HT-29 cells on the transcriptional level. Pointing to the




-stimulated IL-8 secretion in HT-29 cells, butyrate




modulated neutrophil migration significantly: reduction towards Caco-2 and enhancement towards HT-





-stimulated IL-8 secretion by butyrate-exposed HT-29 cells substan-
tially. Immunomodulatory effects of butyrate on IEC are functionally relevant for neutrophil migration.




-mediated IL-8 secretion in a subpopulation of IEC may








The inflammatory bowel diseases, Crohn’s disease and ulcerative
colitis are thought to result from a perturbed immune response to
luminal antigens in a genetically and environmentally disposed
host [1]. Peptide regulatory factors such as cytokines, chemokines
and growth factors contribute substantially to the initiation and
perpetuation of intestinal inflammation leading to activation of
mucosal cell populations and recruitment of circulating leuco-
cytes. IL-1 is a proinflammatory cytokine of pivotal importance
for the pathogenesis of inflammatory bowel diseases produced by
activated monocytes, macrophages, fibroblasts, smooth muscle
cells and endothelial cells [2]. Intestinal epithelial cells (IEC)
form a physical barrier, but increasing evidence suggests that
these cells have an active role in the initiation and perpetuation of
intestinal inflammation. Human colonic carcinoma cell lines and
primary intestinal epithelial cells have been shown to respond
to IL-1 and other proinflammatory cytokines and to produce
chemokines such as IL-8, a chemotactic and activating peptide for
neutrophils [3]. Due to their exposed localization at the luminal
surface and their involvement in mucosal immune homeostasis,
IEC have become a potential target for anti-inflammatory
treatment strategies comprising inhibition of proinflammatory
cytokine production, receptor binding and signalling as well
as induction, up-regulation or delivery of anti-inflammatory or
immunoregulatory cytokines.
Butyrate, a short-chain fatty acid derived from bacterial fer-
mentation of luminal carbohydrates, is the principal energy
source of the colonic epithelium [4] and modulates enterocyte dif-








 support the assumption that butyrate has
immunoregulatory effects on IEC and other mucosal cell popu-
lation [7–10]. Typically, butyrate modulates gene expression
induced by other factors through either stimulatory or inhibitory
actions. Some of these activities are attributed to hyperacetylation
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studies of administration of butyrate enemas to patients with
ulcerative colitis have produced promising results. In the majority
of larger trials, however, the results were unsatisfactory [12–14].
Insufficient clinical efficacy of butyrate enemas could be due to
proinflammatory actions of butyrate on the target cell population,
mainly IEC. In the present study we focused on the functional
consequences of butyrate-modulated proinflammatory IL-8






Transformed human colonic HT-29/p epithelial cells (American
Type Culture Collection, Bethesda, MD, USA; ATCC HTB 38)
and HT-29/MTX cells, permanently differentiated upon transient
exposure to methotrexate (generously provided by Dr Lesuffleur,
INSERM, Villejuif, France) [15] were used between passages 20–





, Long Island, NY, USA) supplemented with 10% heat-


















g/ml, amphotericin B 250 ng/ml; Sigma, St Louis,
MO, USA).
Caco-2 cells (ATCC HTB-37) at passages 40–60 were cultured





















Human intestinal primary epithelial cell (HIPEC) lines in
long-term cultures were established as described previously [16].
Briefly, isolated crypt cells from surgically resected specimens
were cultured in mucosal tissue derived autologous growth factor
containing F12 medium supplemented with epidermal growth fac-
tor, insulin, transferin, retinoic acid and hydrocortisone (HIPEC
medium). At the time of the experiments HIPECs were grown in
HIPEC medium without autologous growth factor but supple-
mented with 5% dialysed fetal calf serum (Summit Biotech,
Atlanta, GA, USA). HIPECs were derived from normal areas (at
least 10 cm away from the tumour) of transverse colon (HIPEC-
TDT), sigmoid (HIPEC-JHS) and rectum (HIPEC-MJR) from
three different individuals with colon cancer.
The study was conducted in accordance with the second Hel-
sinki Declaration.










 (R&D Systems, Minneapolis, MN, USA). HT-




(R&D Systems) or lipopolysaccharide (LPS, strain 0127: B8;





. Neutralizing monoclonal anti-IL-8 antibody and the IgG



















































RNA extraction and amplification by reverse-transcription–
polymerase chain reaction (RT-PCR)
 
RNA was isolated using the Trizol method (Life Technologies,




g of total RNA was reverse tran-




l containing 25 U RNasin (Promega,




 dNTPs (dATP, dCTP, dGTP and










). The reaction was carried out for





















l of the reverse tran-




 PCR buffer (Perkin Elmer, Foster City, CA,




 dNTPs and 1.25 U of
Thermo aquaticus polymerase (Perkin Elmer). PCR was carried
out in a 9600 Perkin-Elmer cycler set for various cycles to monitor
the linearity of the amplification. The results presented were













C for 2 min




C for 5 min.
The PCR products (1/5 volume) were electrophoresed on 2%
agarose gels containing ethidium bromide. A negative from the
photographs of the gels (Polaroid 665 film, Polaroid Corp.,
Cambridge, MA, USA) was scanned with a silverscanner II PS
v2·1a connected to a Power Mac 8100/80 computer and analysed
with the Adobe Photoshop 2·5.1 software. As a negative control,
tubes with no nucleic acid or with RNA only were used. The






























 (product length 235 bp);




















































(product length 493 bp).
 
Transfections and luciferase reporter assay
 










B)LUC and (mAP-1)LUC were a generous gift
from Dr G. Wu, Philadelphia [17]. Transfected cells were incu-
bated overnight after which the DNA/lipofectamine media was
replaced with the serum-containing media and the cells incubated




(1 ng/ml) for 12 h after which extracts were prepared using
enhanced luciferase assay reagents (Berthold Detection Systems,
Pforzheim, Germany). Luciferase assays were performed on a
luminometer for 20 s (Berthold Detection System) and results
were normalized for extract protein concentration measured with




Chemotactic activity of cell culture supernatants was assayed
by a modified Boyden chamber assay. Neutrophils from healthy
donors were obtained by spontaneous sedimentation over Ficoll
for 40 min at room temperature. Each well of a 24-well cell cul-
















 in PBS, positive
control) or cell culture supernatants, respectively. Collagen pre-





l of the leucocyte-rich plasma containing approximately
750 000 neutrophils. After 20 min of incubation the inserts were
removed and the migrated cells transferred from the well into 5-





l fluoresceinated monoclonal antibody against LECAM-1
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 cells/ml) were cultured overnight in the pres-




 butyrate. Butyrate-treated and -untreated cells




 (1 ng/ml) for 24 h in triplicate. The IL-8









































Butyrate (5 mM) – – +       + 




(CD62L-FITC, BD-Pharmingen) for 15 min and counterstained





l of a red-fluorescent bead suspension was added for
counting purposes (all remaining components were obtained
from ORPEGEN, Heidelberg, Germany). Samples were analysed
on a bench-top flow cytometer (FACScan, BD, San José, CA,
USA) equipped with an air-cooled argon laser emitting 15 mW
at 488 nm adjusted for lymphocyte immunophenotyping with
CaliBRITETM beads (BD). To obtain relative cell concentrations
data acquisition was stopped when 2000 beads were counted.
List mode data were analysed for neutrophil counts as defined





light scatter, shape change in terms of forward scatter light
intensity and fluorescence intensity of CD62 expression. N-
formylmethionylleucylphenylalanine used as a positive control
leads, on average, to a 100-fold migration of neutrophils into the
lower compartment compared to PBS, accompanied by a shape
change and CD62 down-regulation.
 
IL-8 enzyme-linked immunosorbent assay
 
A human IL-8 enzyme-linked immunosorbent assay (ELISA)
of cell culture supernatants was performed in triplicate according








 standard error of the mean (s.e.).
Differences between the groups were compared using analysis of












Butyrate differentially modulates the proinflammatory 
responsiveness of intestinal epithelial cells: potential role of 
cytokine receptor expression
 
In accordance with findings by others, in our hands exposure of
IEC lines to butyrate decreased cell proliferation without affect-
ing cell viability, and instigated cellular differentiation as assessed





-stimulated IL-8 secretion by Caco-2 cells previously exposed








 0·05), while exposure of HT-29/p




 increased the IL-8
content in cell-free supernatant assayed by specific ELISA
approximately four- to sixfold (not shown). In differentiated HT-




-stimulated IL-8 secretion by
butyrate was even stronger, ranging from a threefold increase at




 to a seven- and ninefold increase at 1 and




, respectively (not shown). We further used pri-
mary intestinal epithelial cells, HIPEC lines from three different
individuals with colon cancer to assess the effects of butyrate in





 significantly up-regulated the IL-8

















 0·05) diminished this response, although basal lev-
els were not reached (Fig. 1).
Transfection studies with promoter–luciferase constructs
were performed to investigate whether effects of butyrate were
mediated at the transcriptional or translational level. Induction of
IL-8 gene expression by proinflammatory stimuli has been shown
to comprise activation, nuclear translocation and sequence-





HT-29/p and Caco-2 cells were transiently transfected with the
full-length IL-8 promoter–luciferase construct or with similar
























stimulation (Fig. 2a). By contrast, up-regulated secretion of IL-8
protein by butyrate in IL-1
 
b-stimulated HT-29/p cells was paral-
leled by substantially increased IL-8 full-length promoter activity
(P < 0·01) (Fig. 2b). Further analysis with the mutant constructs
showed that enhancement of IL-1b-stimulated IL-8 promoter
activity by butyrate was dependent on kB, but independent of AP-
1 binding (Fig. 2c); however, butyrate alone induced the IL-8 pro-
moter by a mechanism that was only partially dependent on
AP-1 and kB and not paralleled by IL-8 secretion.
IL-1 effects are transduced after binding of the ligand to the
signalling receptor IL-1RI, while the IL-1RII does not contain an
intracellular domain and functions as a decoy receptor [18]. To
assess the possibility that butyrate-mediated modulation of cytok-
ine receptors was responsible for the observed up-regulation of
IL-1b-induced secretion of IL-8 in HT-29 cells, expression of IL-
1RI and IL-1RII mRNA in butyrate-exposed HT-29/p cells was
determined by RT-PCR and assessed semiquantitatively by
densitometry compared to expression of the housekeeping gene
b-actin. Upon exposure of HT-29/p cells to butyrate IL-1RI
steady-state transcript levels were significantly up-regulated
(Fig. 3), while IL-1RII levels remained unchanged (not shown).
In contrast, no increase was seen in Caco-2 cells (not shown).
Butyrate-mediated modulation of IL-8 secretion by intestinal 
epithelial cells is functionally relevant for neutrophil migration
While proinflammatory chemokine induction in IEC has been the
focus of many studies, its functional significance in comparison to
chemokine production by lamina propria immune cells has been
debated. We performed migration assays to evaluate the impact
of IL-1b-mediated IEC-derived IL-8 secretion on neutrophil
56 U. Böcker et al.
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Fig. 3. Butyrate modulates receptor mRNA expression in HT-29/p cells.
Cells were treated with 5 mM butyrate for 24 h prior to extraction of RNA
and RT-PCR analysis. After pretreatment with butyrate, cells were treated
with IL-1b for various time-points before RT-PCR for IL-1RI. Band inten-
sity was analysed semiquantitatively by densitometry and related to the
expression of b-actin. Two more experiments gave similar results. , 0 h;


















Butyrate (5 mM) – + – +
IL-1b  (1 ng/ml) – – + +
Fig. 2. Involvement of transcription factor activation in butyrate-modu-
lated proinflammatory IL-8 secretion. (a) Caco-2 cells were transfected
transiently with a full-length IL-8 promoter–luciferase construct and
exposed to 5 mM butyrate for 12 h and to proinflammatory stimuli for
additional 12 h as indicated. Three additional experiments gave similar
results. (b) HT-29/p cells were transfected transiently with a full-length IL-
8 promoter–luciferase construct and exposed to 5 mM butyrate for 12 h
and to IL-1b (1 ng/ml) for an additional 12 h. (c) HT-29/p cells were
transfected with an IL-8 promoter–luciferase construct with a mutant
(defective) AP-1 (mAP-1) or kB (mkB) binding site. Data are means of
triplicates. Four additional experiments gave similar results.
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chemokinesis and activation. Neutrophils were exposed to condi-
tioned media of Caco-2 and HT-29/p cells. As a positive control,
cells were stimulated by N-formylmethionylleucylphenylalanine
at 10-6 M. Butyrate and the IL-1b protein had no intrinsic chemo-
tactic effect on neutrophils in the absence of conditioned media.
Supernatants from both IL-1b-stimulated Caco-2 and HT-29/p
cells induced migration of neutrophils. This process was dimin-
ished significantly by exposure of Caco-2 cells to butyrate
(Fig. 4a) but enhanced significantly by butyrate preincubation
exposure of HT-29/p cells (Fig. 4b). Emphasizing the major role of
IL-8 for neutrophil chemokinesis, neutralization of IL-8 by a
monoclonal antibody diminished neutrophil migration signifi-
cantly (P < 0·05) in response to butyrate-treated HT-29/p cells,
while the control antibody had no significant effect (Fig. 4c).
Pharmacological abrogation of butyrate-mediated enhancement 
of IL-8 secretion in HT-29/p cells
To abrogate the enhanced proinflammatory IL-1b-mediated IL-8
secretion pharmacologically, we applied specific inhibitors of sig-
nal transduction pathways and also clinically relevant medications
used in the treatment of inflammatory bowel diseases that have
been shown to possess in vitro inhibitory effects on proinflamma-
tory transcription factor activation. Levels of IL-1b-stimulated
IL-8 (100%) remained unchanged upon exposure to genistein, an
inhibitor of tyrosine kinases, and to wortmannin, an inhibitor of
the phosphatidyl inositol-3¢-kinase (Fig. 5). Release of calcium by
the ionophore A23187 and blockade of tyrosine phosphatase
activity by orthovanadate reduced the IL-8 content in the super-
natant by more than 75% in HT-29/p cells (Fig. 5). Staurosporine,
an inhibitor of protein kinase C activation, abrogated IL-8
secretion down to baseline levels (Fig. 5); however, cell prolifer-
ation and vitality were markedly reduced. In contrast, action of
orthovanadate was not due to impaired cell viability as assessed
by trypan blue exclusion and by LDH levels in supernatants.
However, calcium release and blockade of tyrosine phosphatase
activity did not specifically abrogate butyrate-mediated effects
(data not shown).
Surprisingly, dexamethasone at 10-9-10-4 M did not reduce IL-
8 levels induced by IL-1b (Fig. 6a), either in the presence or
absence of butyrate. However, the dexamethasone used was bio-
logically active, as it inhibited LPS-stimulated TNF-a production
by mouse splenocytes (data not shown). Interestingly, 5-aminosal-
icylic acid (mesalamine) substantially reduced IL-1b stimulated
IL-8 secretion (Fig. 6a), while sulphasalazine abrogated IL-8
secretion to levels comparable to unstimulated controls in a
Immunomodulatory effects of butyrate on IEC 57



































































dose-dependent fashion (Fig. 6a,b). Sulphasalazine did not
appear to be toxic at the doses investigated by cell morphological
analyses and assessment of LDH release into the culture super-
natant. These results demonstrate that 5-ASA products can abro-
gate the up-regulation of IL-1b-induced chemokine expression by
butyrate.
DISCUSSION
This study was designed to explore modulation of IL-8 secretion
in IEC by the short-chain fatty acid butyrate, to analyse functional
consequences of exposing IEC to butyrate and to provide exam-
ples of pharmacological antagonism. This investigation provides
evidence that alteration of IL-8 release - enhancement in HT-29
and inhibition in Caco-2 cells - is functionally relevant for neu-
trophil migration. Furthermore, IL-1b stimulated IL-8 secretion
in HT-29/p cells is completely abrogated in the presence of sul-
phasalazine, a clinically efficacious drug in the treatment of ulcer-
ative colitis, thus providing a potential tool to synergistically
enhance the protective properties of butyrate on IEC metabolism
and restitution, while blocking any proinflammatory conse-
quences of butyrate administration.
We focused on IL-1b-mediated chemokine induction in IEC
for two reasons. First, IL-1 has been shown to be important in the
pathogenesis of intestinal inflammation. Secondly, as opposed to
other proinflammatory mediators such as TNF-a [19], both trans-
formed and non-transformed IEC express the IL-1R and respond
to IL-1b. Upon binding of IL-1b to the IL-1R, signal transduction
is activated through the IL-1R associated kinase and its adaptor
proteins through the NF-kB and Jun–N-terminal kinase pathways
followed by nuclear translocation of the transcription factors NF-
kB and AP-1 [20–24]. Binding of transcription factors to the cor-
responding promoter sequence initiates chemokine gene expres-
sion. Our migration assay for neutrophils emphasizes clearly the
functional importance of this IL-1b-mediated gene activation and
chemokine release by IEC. It illustrates further the potential to
modulate this particular effector function of IEC significantly.
Consistant with previous ELISA results, the significantly
Fig. 4. Butyrate pretreatment modulates differently chemokinesis of neutrophils in response to conditioned medium of Caco-2 and HT-
29/p cells stimulated by 1 ng/ml IL-1b for 12 h. Neutrophils obtained by spontaneous sedimentation were transferred onto precoated cell
culture inserts and exposed to conditioned media. Migrated cells were quantified (counts related to 2000 beads given in figure) and
characterized by flow cytometry. (a) Caco-2 cells: media, negative control; IL-1b, IEC stimulation by IL-1b; butyrate, IEC pretreatment
with 5 mM butyrate in culture media; butyrate + IL-1b, IEC pretreatment with 5 mM butyrate followed by IL-1b stimulation. (b) HT-29/p
cells: PBS, negative control; IL-1b, IEC stimulation by IL-1b; butyrate, IEC pretreatment with 5 mM butyrate; butyrate + IL-1b, IEC
pretreatment with 5 mM butyrate followed by IL-1b stimulation (P < 0·05 versus butyrate, P < 0·01 versus butyrate + IL-1b). (c) HT-29/p
cells: butyrate + IL-1b + goat IgG, IEC pretreatment with 5 mM butyrate followed by IL-1b stimulation in the presence of the IgG goat
control antibody (P < 0·05 versus butyrate + IL-1b + anti-IL-8); butyrate + IL-1b + anti-IL-8, IEC pretreatment with 5 mM butyrate followed
by IL-1b stimulation in the presence of the monoclonal anti-IL-8 antibody (P < 0·05 versus butyrate + IL-1b).Data are means of triplicates
± s.d. Two more experiments gave similar results.
58 U. Böcker et al.
© 2003 Blackwell Publishing Ltd, Clinical and Experimental Immunology, 131:53–60
opposing functional effects of butyrate on two colon-derived IEC
lines in our study are remarkable: enhancement of neutrophil
migration in response to HT-29/p cells, and reduction in response
to Caco-2 cells. Evidence has been provided that cellular differ-
entiation alters the immunoregulatory potential of IEC, leading
to decreased IL-1 responsiveness of differentiated surface-like
cells [25,26]. Our data suggest that butyrate reverses this phenom-
enon at least partially: when comparing moderately differentiated
parental HT-29/p to methotrexate-differentiated HT-29 cells, the
relative augmentation of the IL-1b-stimulated IL-8 secretion by
butyrate increased with the degree of cellular differentiation. This
assumption appears to contradict the potential of butyrate to dif-
ferentiate IEC and to induce the icIL-1RaI which antagonizes IL-
1b-mediated IEC effector functions [25]. However, we focused in
our study on early events after short-term exposure to butyrate,
and cellular differentiation was not completed at this time. Caco-
2 cells have been the target of studies on butyrate effects per-
formed by others generating conflicting data [8,27]. We confirm
that butyrate diminishes IL-1b-stimulated IL-8 secretion by Caco-
2 cells. Ongoing investigations are designed to elucidate the
molecular mechanisms responsible for the cell-line specific differ-
ences in butyrate responses, and we hypothesize at this point only
that cellular differentiation may be a principal factor. It is note-
worthy that butyrate-mediated modulation of the proinflamma-
tory responsiveness of primary IEC was similar to that seen in
Caco-2 cells, indicating that Caco-2 cells might be more represen-
tative for the in vivo situation than HT-29/p cells. Furthermore,
RT-PCR for specific receptor mRNA expression suggested that
butyrate affects the receptor concentration. Conspicuously,
butyrate substantially increased steady-state transcript levels of
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Fig. 6. Pharmacological abrogation of IL-1b-stimulated and butyrate-
enhanced IL-8 protein secretion. (a) HT-29/p cells were treated with
butyrate or media alone and stimulated by IL-1b (1 ng/ml) for 24 h in the
presence or absence of mesalamine (5-ASA), sulphasalazine (SASP) or
dexamethasone (Dex) prior to assessment of supernatants for IL-8 protein
content by specific ELISA. (b) Increasing doses of sulphasalazine (SASP)
were used to modulate IL-8 secretion induced by IL-1b in the presence or
absence of butyrate. Data are presented as percentage of control level
obtained in the absence of SASP. Data are means of triplicates. Two more
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Fig. 5. Inhibition of IL-8 protein secretion by blockade of early signalling
events. HT-29/p cells were exposed to orthovanadate (1 mM), staurospo-
rine (1 mM), genistein (20 mM), wortmannin (10 mM) and the calcium iono-
phore A23187 (10 mM) for 30 min prior to addition of 5 mM butyrate to
the culture media for 24 h. Cells were then stimulated by 1 ng/ml of IL-1b
for 12 h, and supernatants assessed for IL-8 content. IL-8 levels of controls
treated with butyrate alone and then stimulated by IL-1b are considered




























































the signalling receptor IL-1RI, while mRNA expression of the
decoy receptor IL-1RII remained unchanged.
Pharmacological agents were applied to substantially decrease
or to abrogate IL-8 secretion stimulated by IL-1b. We chose two
classes of anti-inflammatory drugs used widely as first-line treat-
ment of the inflammatory bowel diseases. Corticosteroids, used to
treat a variety of inflammatory diseases, inhibit various proinflam-
matory pathways and interfere with nuclear translocation of NF-
kB by up-regulating expression of the cytoplasmic inhibitor IkB
[28,29]. The corticosteroid dexamethasone inhibited IL-8 gene
expression induced by Entamoeba histolytica in Caco-2 and T84
cells [30]. Considering the data presented by others and by us
demonstrating dependence of NF-kB for proinflammatory induc-
tion of IL-8 in IEC, dexamethasone surprisingly had no inhibitory
effect in the IEC lines used in this investigation - neither in the
absence nor in the presence of butyrate - yet was biologically
active in unfractionated stimulated murine splenocytes.
Mesalamine, 5-aminosalicylic acid, is a free aminosalicylate, while
sulphasalazine is an azo-conjugated aminosalicylate. Both agents
inhibit gut inflammation in ulcerative colitis and to a lesser degree
in Crohn’s disease. Mesalamine appears to regulate NF-kB activ-
ity by modulating the phosphorylation of one of its transcription-
ally active proteins [31]. The anti-inflammatory action of
sulphasalazine is attributed to two functions. It is a prodrug for
mesalamine, but the parent compound seems to have additional
activities. It was shown that sulphasalazine, but not its compo-
nents mesalamine or sulphapyridine, inhibited NF-kB activation
by TNF-a [32]. We now demonstrate that IL-1b-stimulated IL-8
secretion is inhibited dose-dependently by sulphasalazine as well,
and that sulphasalazine was superior to mesalamine and to dex-
amethasone. This adds in vitro credit to a compound that in clin-
ical therapies has been frequently replaced by mesalamine.
Therapeutic application of butyrate in inflammatory bowel
diseases is based on the beneficial effects of this short-chain fatty
acid on IEC proliferation and restitution. However, the present
study demonstrates potentially counterbalancing proinflamma-
tory effects of butyrate on a subpopulation of IEC in the presence
of IL-1b, with stimulation of cytokines with functional chemotac-
tic activity. These discordant activities of butyrate may account for
the inconsistent clinical results of butyrate administration. Phar-
maceutical agents used in the treatment of intestinal inflamma-
tion antagonize this effect, providing a potential means to
improve clinical efficacy of butyrate. Clinical trials comparing
combined treatment of ulcerative colitis with butyrate and sul-
phasalazine versus application of either component alone would
address the clinical implications of our in vitro observations.
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